GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Resonate Blends Inc (OTCPK:KOAN) » Definitions » Debt-to-EBITDA

Resonate Blends (Resonate Blends) Debt-to-EBITDA : -8.26 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Resonate Blends Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resonate Blends's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.45 Mil. Resonate Blends's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Resonate Blends's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.30 Mil. Resonate Blends's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -8.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Resonate Blends's Debt-to-EBITDA or its related term are showing as below:

KOAN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.17   Med: -0.17   Max: 1.22
Current: -3.17

During the past 13 years, the highest Debt-to-EBITDA Ratio of Resonate Blends was 1.22. The lowest was -3.17. And the median was -0.17.

KOAN's Debt-to-EBITDA is ranked worse than
100% of 658 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs KOAN: -3.17

Resonate Blends Debt-to-EBITDA Historical Data

The historical data trend for Resonate Blends's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resonate Blends Debt-to-EBITDA Chart

Resonate Blends Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.38 -0.40 1.22 -3.17

Resonate Blends Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.76 -1.14 -1.68 -7.85 -8.26

Competitive Comparison of Resonate Blends's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Resonate Blends's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resonate Blends's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Resonate Blends's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Resonate Blends's Debt-to-EBITDA falls into.



Resonate Blends Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resonate Blends's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.446 + 0) / -0.771
=-3.17

Resonate Blends's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.446 + 0) / -0.296
=-8.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Resonate Blends  (OTCPK:KOAN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Resonate Blends Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Resonate Blends's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Resonate Blends (Resonate Blends) Business Description

Traded in Other Exchanges
N/A
Address
26565 Agoura Road, Suite 200, Calabasas, CA, USA, 91302
Resonate Blends Inc is a cannabis/hemp-based holding company. It is focused on a vertically integrated and valued-added Wellness and Lifestyle brand.
Executives
Richard Hoge 10 percent owner C/O JIM KEARNEY, 760 SW 9TH AVE. STE 3000, PORTLAND OR 97205
Pamela Kerwin officer: Chief Operating Officer 26565 AGOURA ROAD, SUITE 200, CALABASAS CA 91302
Geoffrey Selzer director, officer: Chief Executive Officer 26565 AGOURA ROAD, SUITE 200, CALABASAS CA 91302
David Thomas Thielen 10 percent owner, officer: COO 1940 CONTRA COSTA BLVD., PLEASANT HILL CA 94523
Nick Allen Miniello 10 percent owner, officer: VP of Sales 1940 CONTRA COSTA BLVD., PLEASANT HILL CA 94523
Wais Asefi director, 10 percent owner, officer: CEO 1940 CONTRA COSTA BLVD., PLEASANT HILL CA 94523
Sterling John M Iii director
Gregory Oliver Sargent 10 percent owner 1609 FAIRFIELD BEACH ROAD, FAIRFIELD CT 06824
Steven Richard Deerwester officer: Vice President 3125 DARTMOUTH PLACE, CUMMING GA 30041
David G Kane other: Controller 50 JOE LEE DRIVE, SHARPSBURG GA 30277
I Sigmund Mosley director 945 E PACES FERRY RD, SUITE 2450, ATLANTA GA 30326
Vincent J Dooley director 2859 PACES FERRY ROAD, SUITE 1000, ATLANTA GA 30339
Spencer John N Jr director 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Marsha K Calfee officer: VP of Product Development
Jeffrey Longoria officer: VP of Sales